Jiyoung Rhee
Overview
Explore the profile of Jiyoung Rhee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rhee J, Park H
Korean J Med Educ
. 2025 Mar;
37(1):35-45.
PMID: 40049681
Purpose: Debriefing after simulation-based healthcare education (SBHE) is challenging. Educators' debriefing skills are essential to the success of learning. For debriefing skill training, we designed a simulation course with the...
2.
Rhee J, Jo J, Han S, Kwon J
Ann Dermatol
. 2021 Apr;
31(2):201-203.
PMID: 33911569
No effective systemic chemotherapy is well-established in basal cell carcinoma. We report a case with three simultaneous malignancies: colon cancer, basal cell carcinoma, and smoldering multiple myeloma. The patient was...
3.
Rhee J, Kwon J, Han S, Kim S, Park C, Jeon J, et al.
Kidney Res Clin Pract
. 2017 Dec;
36(4):342-348.
PMID: 29285426
Background: Although the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation has been recommended for accurate estimates of glomerular filtration rate (eGFR), there is little information regarding differences in GFR estimates...
4.
Lee D, Im S, Kim Y, Yang Y, Rhee J, Na I, et al.
Cancer Res Treat
. 2017 Jan;
49(3):807-815.
PMID: 28111425
Purpose: While tumor markers (carbohydrate antigen 19-9 [CA 19-9] and carcinoembryonic antigen [CEA]) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated....
5.
Jo J, Kim J, Kim J, Hyun C, Rhee J, Kwon J, et al.
Cancer Res Treat
. 2015 Feb;
48(1):393-7.
PMID: 25715772
Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term...
6.
Rhee J, Kim G, Lee C, Kwon J, Han S, Kim Y, et al.
Radiat Oncol J
. 2015 Jan;
32(4):262-5.
PMID: 25568855
Tamoxifen and radiotherapy are used in breast cancer treatment worldwide. Radiation recall dermatitis (RRD), induced by tamoxifen, has been rarely reported. Herein, we report a RRD case induced by tamoxifen....
7.
Eom B, Lee J, Lee J, Kim M, Ryu K, Choi I, et al.
J Surg Oncol
. 2011 Sep;
105(3):310-5.
PMID: 21898415
Background: A tumor thrombus in the portal vein originating from gastric cancer is a rare condition. Little is known about the development of portal vein tumor thrombus (PVTT) and its...
8.
High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
Rhee J, Han S, Cha Y, Ham H, Kim H, Oh D, et al.
Breast Cancer Res Treat
. 2010 Oct;
125(1):107-14.
PMID: 20936340
Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the biomarkers from serum of patients receiving lapatinib and capecitabine...
9.
Rhee J, Han S, Oh D, Im S, Kim T, Bang Y
J Gastroenterol Hepatol
. 2010 Aug;
25(9):1537-42.
PMID: 20796152
Background And Aim: Few systematic studies have been published on prognosis and clinical outcome of gastric cancer patients with disseminated intravascular coagulation (DIC) as the first presentation of malignancy. We...
10.
Rhee J, Han S, Oh D, Kim J, Im S, Han W, et al.
BMC Cancer
. 2008 Oct;
8:307.
PMID: 18947390
Background: Triple-negative (TN) breast cancer, which is defined as being negative for the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER-2), represents...